Signs and Symptoms of Maple Syrup Urine Disease

Jordi Marino, Department of Neurosurgery, Medical University of Gdansk, Gdansk, Poland, Email: jordi12345@gmail.com

Received: 12-May-2022, Manuscript No. JMOLPAT-22-68127; Editor assigned: 16-May-2022, Pre QC No. JMOLPAT-22-68127 (PQ); Reviewed: 01-Jun-2022, QC No. JMOLPAT-22-68127; Revised: 08-Jun-2022, Manuscript No. JMOLPAT-22-68127 (R); Published: 16-Jun-2022

Description

Branched-chain amino acids are impacted by Maple Syrup Urine Disease (MSUD), an autosomal recessive metabolic illness. This particular case of organic academia, named after the unique sweet smell of the affected infants’ urine and earwax, especially before diagnosis and during periods of acute sickness. The indications and symptoms of maple syrup urine disease can be categorised, as well as the hereditary aetiology. The classic form of this illness is the most prevalent and severe type; it manifests shortly after birth and, if left untreated, results in symptoms that worsen over time and never go away. Variant forms of the disorder may not manifest until later in infancy or youth, and they often have milder symptoms that may only manifest during periods of fasting, stress, or illness. However, if ignored, these forms of the disorder can still cause mental and physical difficulties [1,2].

Signs and symptoms

The condition is so named because, when a person enters a metabolic crisis, their urine has a sweet, maple syrup-like odour. During a metabolic crisis, the stench can also be detected in an affected person’s ear wax. The aroma of maple syrup can be compared to that of fenugreek in communities where that herb is unfamiliar, and fenugreek consumption can cause urine to take on that aroma. The degree of remaining enzyme activity has a significant impact on the symptoms of MSUD, which vary widely amongst patients [3-5].

Classic MSUD

Within the first 24 to 48 hours, infants with classic MSUD will start to exhibit mild symptoms. Lethargy, impatience, and poor bottle- or breast-feeding are all subtle indications. The baby will thereafter display more pronounced focal neurologic symptoms. These neurological symptoms, which cause convulsions and unconsciousness include athetoid, hypertonia, spasticity, and opisthotonus. Untreated MSUD will result in central neurologic dysfunction, respiratory failure, and death. The risks of metabolic decompensation and bone mass loss, which can result in osteoporosis, pancreatitis, and intracranial hypertension, persist even after MSUD has been controlled. Intellectual disability and behavioural difficulties are additional classic MSUD symptoms that may be present [6].

Intermediate MSUD

Compared to classic MSUD, intermediate MSUD has higher levels of lingering enzyme activity. Most kids with intermediate MSUD receive their diagnosis between the ages of 5 months and 7 years. Intermediate MSUD also exhibits symptoms that are similar to those of classic MSUD.

Intermittent MSUD

Individuals with intermittent MSUD will experience normal growth and intellectual development in contrast to those with classic and intermediate MSUD. When a person is under stress, doesn’t eat, or is sick, lethargic symptoms and a distinctive maple syrup odour appear. There is still a chance of a metabolic crisis that results in seizures, coma, and brain damage [7,8].

Thiamine-response MSUD

The signs and symptoms of intermediate MSUD are similar to those of thiamine-responsive MSUD. Rarely do newborns exhibit symptoms.

Later onset

Depending on how severe the condition is, MSUD symptoms may also develop over time. Untreated symptoms of the condition include extreme or erratic behaviour and moods, hallucinations, lack of appetite, weight loss, anaemia, diarrhoea, vomiting, dehydration, lethargy, oscillating hypertonia and hypotonia, ataxia, seizures, hypoglycemia, ketoacidosis, opisthotonus, pancreatitis, rapid neurological decline, and coma in older people and during times of metabolic crisis. If there is no therapy, cerebral edema-related death will probably happen. Additionally, MSUD patients undergo atypical disease progression in mild illnesses that might cause long-term harm.

Prevention

Infants with two faulty copies of the BCKD gene cannot be treated to stop the pathology of MSUD from showing up. To screen for the condition, however, couples may speak with genetic counsellors and undergo DNA testing. The condition can also be detected in an unborn kid in the pregnancy via DNA testing.

References

1. Fahira A, Li Z, Liu N, Shi Y. Prediction of causal genes and gene expression analysis of attention-deficit hyperactivity disorder in the different brain region, a comprehensive integrative analysis of ADHD. Behav. Brain Res 2019;364:183-192.

   [Crossref] [Google scholar] [Pubmed]

2. Chapman KA, Gramer G, Viall S, Summar ML. Incidence of maple syrup urine disease, propionic acidemia, and methylmalonic aciduria from newborn screening data. Mol. Genet. Metab. Rep 2018;15:106-109.

   [Crossref] [Google scholar] [Pubmed]

3. Burrage LC, Nagamani SC, Campeau PM, Lee BH. Branched-chain amino acid metabolism: From rare Mendelian diseases to more common disorders. Hum. Mol. Genet 2014;23:R1-R8.

   [Crossref] [Google scholar] [Pubmed]

4. Sener RN. Maple syrup urine disease: Diffusion MRI, and proton MR spectroscopy findings. Comput. Med. Imaging Graph 2007;31:106-110.

   [Crossref] [Google scholar] [Pubmed]

5. McEntee WJ, Crook TH. Glutamate: Its role in learning, memory, and the aging brain. Psychopharmacol. (Berl) 1993;111:391-401.

   [Crossref] [Google scholar] [Pubmed]

6. Wang R, Reddy PH. Role of Glutamate and NMDA Receptors in Alzheimer’s Disease. J. Alzheimers Dis 2017;57:1041–1048.

   [Crossref] [Google scholar] [Pubmed]                                                                                                                                                                  

7. Murrough JW, Abdallah CG, Mathew SJ. Targeting glutamate signalling in depression: Progress and prospects. Nat. Rev. Drug Discov 2017;16:472–486.

   [Crossref] [Google scholar] [Pubmed]

8. Noroozi R, Taheri M, Omrani MD, Ghafouri-Fard S. Glutamate receptor metabotropic 7 (GRM7) gene polymorphisms in mood disorders and attention deficit hyperactive disorder. Neurochem. Int 2019;129:104483.

   [Crossref] [Google scholar] [Pubmed]

Copyright: © 2022 The Authors. This is an open access article under the terms of the Creative Commons Attribution NonCommercial ShareAlike 4.0 (https://creativecommons.org/licenses/by-nc-sa/4.0/). This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.